Telaprevir in the Treatment of Acute HCV Infection in HIV-infected Men

[1]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[2]  V. Soriano,et al.  Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.

[3]  M. Manns,et al.  Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[4]  L. Taylor,et al.  Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  V. Martel-Laferrière,et al.  Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  V. Miller,et al.  Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Branch,et al.  Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Webster,et al.  Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and Ribavirin , 2013, International journal of STD & AIDS.

[9]  V. Miller,et al.  Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents , 2012, Hepatology.

[10]  A. Branch,et al.  Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Kaldor,et al.  Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection , 2012, AIDS.

[12]  L. Naeger,et al.  Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment , 2012, Hepatology.

[13]  C. Datz,et al.  Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. , 2012, Gastroenterology.

[14]  Michael Adler,et al.  Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.

[15]  E. Schiff,et al.  Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[16]  J. V. D. van der Meer,et al.  Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration , 2011, AIDS.

[17]  R. Bruno,et al.  Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. , 2011, The Journal of infectious diseases.

[18]  C. Cordes,et al.  Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): The "Real-life Setting" proves the concept , 2011 .

[19]  Joseph Eliahoo,et al.  Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men , 2010, Gut.

[20]  S. Pol,et al.  Treatment of acute hepatitis C in human immunodeficiency virus–infected patients: The HEPAIG study , 2010, Hepatology.

[21]  E. Bottieau,et al.  Surveillance and outbreak reports Hepatitis C virus infection in HIV-infected men who have sex with men : sustained rising incidence in Antwerp , Belgium , 2001 – 2009 , 2010 .

[22]  E. Vittinghoff,et al.  Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco , 2010, PloS one.

[23]  A. Samri,et al.  Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus , 2009, AIDS.

[24]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[25]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[26]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[27]  J. Kaldor,et al.  Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Branch,et al.  Rare birds in North America: acute hepatitis C cohorts. , 2009, Gastroenterology.

[29]  A. Branch,et al.  Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. , 2008, The Journal of infectious diseases.

[30]  C. Katlama,et al.  Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients , 2006, AIDS.

[31]  C. B. Hare,et al.  Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. , 2006, Journal of acquired immune deficiency syndromes.

[32]  Michael J. Rausch,et al.  Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. , 2006, Antiviral therapy.

[33]  B. Gazzard,et al.  Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin , 2005, Journal of acquired immune deficiency syndromes.

[34]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[35]  P. Volberding,et al.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. , 2004, The New England journal of medicine.

[36]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[37]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.